Q-omics provides the consensus-scored RPS8P6 profile across patient tissues and cancer cell-line models. RPS8P6 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPS8P6 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, RPS8P6 RNA expression shows 7,192 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, KIRC, and LSCC as cancer lineages where RPS8P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS8P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS8P6 survival associations across molecular data types. RPS8P6 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS8P6 RNA expression–survival associations across cancer types. High RPS8P6 expression shows unfavorable associations in STAD, MESO, BLCA, GBM, LGG and KICH. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RPS8P6 RNA expression.
This table summarizes RPS8P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS8P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS8P6 shows lower tumor expression in KIRC. The KIRC box plot shows higher RPS8P6 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p = .001).
This table shows molecular features associated with RPS8P6 in patient tissues and cancer cell lines. In patient samples, RPS8P6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
